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 INTRODUCTION
 Barrett’s esophagus (BE) is a precursor to esophageal adeno-
carcinoma (EAC), with an estimated cancer incidence of 
3–6/1,000 person-years ( 1–3 ). EAC has a high mortality and 
a poor 5-year survival rate if it is not diagnosed and treated at 
an early stage ( 4 ). It is thought that the progression of BE to 
EAC occurs through a dysplasia to carcinoma sequence. Con-
sequently, incidence of EAC is increased in BE with high-grade 
dysplasia (HGD) compared with nondysplastic BE (NDBE) 
( 5,6 ). Currently, dysplasia is the only clinical biomarker that 
is commonly used to stratify risk in BE ( 7–9 ). Patients with BE 
undergo periodic endoscopic surveillance to detect dysplasia 
and adenocarcinoma, but it is unclear whether this practice is 
benefi cial ( 10–12 ). In fact, recent evidence suggests that cur-
rent surveillance practices may not prevent cancer death in BE 
patients ( 13 ).
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Genetic Mutations in BE Predict Progression
 Endoscopic screening and surveillance relies on histology from 
random esophageal biopsies, but this process is imperfect owing 
to sampling error and inconsistencies in histological grading. 
Sampling error may in part explain why two-thirds of all adeno-
carcinomas can occur during the fi rst year of follow-up ( 14 ). Once 
samples are collected, another potential source of error arises from 
the interpretation of histology. Agreement between pathologists 
regarding the degree of dysplasia is relatively poor, particularly for 
low-grade dysplasia (LGD) ( 15–18 ). As a result, current surveil-
lance in BE patients is inadequate to accurately predict who will 
progress to EAC. Th e need for other modalities of risk stratifi ca-
tion, in light of the increasing incidence of EAC, has led to the 
development of advanced endoscopic methods and biomarkers 
( 19–23 ). Biomarkers could be especially helpful in identifying 
high-risk individuals, so that surveillance can be performed in an 
eff ective and cost-conscious manner ( 24 ) to facilitate earlier thera-
peutic interventions.
 Molecular biomarkers have promise in identifying early neo-
plastic transformation, as the development of EAC in BE patients 
is associated with increasing genetic instability. In this study, we 
assessed the utility of a measure of genetic aberration, the muta-
tional load (ML), to predict subsequent progression in BE. Pre-
vious work demonstrated that ML correlated with increasingly 
severe histology ( 25 ). Th erefore, we performed a case–control 
study to determine whether the degree of ML present in pre-
progression BE tissue predicted the risk of progression to HGD 
or EAC. We hypothesized that high ML in pre-progression tissue 




 We performed a case–control study comparing ML in pre-pro-
gression tissue of BE patients who progressed to either HGD 
or EAC with those who did not progress. Cases (i.e., progres-
sors) were BE subjects with no dysplasia or LGD at baseline 
who subsequently developed HGD or EAC, with a minimum 
of at least 1 year between the baseline biopsy and the follow-
up biopsy demonstrating progression. Similar to the cases, 
controls (i.e., nonprogressors) had either NDBE or LGD at 
baseline, but had no progression of BE at the follow-up biopsy. 
All dysplasia readings were confirmed by a second expert 
pathologist. Controls were frequency-matched 2:1 to cases by 
age, sex, index biopsy histology, and length of follow-up (time 
from index to outcome biopsy). Study subjects were recruited 
from three sources: Massachusetts General Hospital, Boston, 
MA; Allegheny General Hospital, Pittsburgh, PA; and Path-
Group, Brentwood, TN. Institutional review board approval 
was obtained to collect specimens and patient data from each 
of these sites, and associated institutional review board num-
bers were 2011-P-002116 (27 October 2011), RC-5743 (25 July 
2013), and 28827/1 (22 November 2013), respectively.
 A limited, deidentifi ed data set, including age, sex, and endo-
scopic and histological evaluation, was abstracted from the 
electronic medical records. In addition, archival FFPE (formalin-
fi xed, paraffi  n-embedded) tissue from the pre-progression endos-
copy was retrieved for analysis by the central lab.
 Tissue processing
 FFPE tissue from biopsies taken from cases and controls at the 
index time point was assessed for ML. Hematoxylin and eosin 
(H&E)-stained FFPE slides were examined microscopically 
to identify representative patient histology, either intestinal 
metaplasia or LGD, for microdissection of histological targets 
to determine ML. In patients with NDBE, microscopic sites of 
epithelial cells with no features of dysplasia were selected as tar-
gets, and in patients with LGD cells demonstrating dysplasia 
were selected. H&E-stained slides were used to guide micro-
dissection of recut, unstained, 4-micron-thick, FFPE slides. 
Slides were microdissected for the maximum number of 
histological targets available upon microscopic inspection. 
Microdissection was performed manually, targeting areas in 
which epithelial cells constituted 90% or more of the total cells 
removed. By microscopic estimation, no more than 10% of 
microdissected cells were stromal or infl ammatory cells. Accu-
racy of all microdissections was carefully reviewed. DNA from 
microdissected targets was prepared either through the crude 
lysate method or QIAamp DNA micro kit (QIAGEN Sciences, 
Germantown, MD).
 ML assessments were made with a previously reported panel 
of 10 genomic loci using 24 DNA markers ( 26–31 ). Th e follow-
ing genomic loci (with associated tumor suppressor genes) were 
included in the panel: 1p (CMM1, L-myc), 3p (VHL, HoGG1), 5q 
(MCC, APC), 9p (CDKN2A), 10q (PTEN, MXI1), 17p (TP53), 
17q (NME1), 18q (DCC), 21q (TFF1, PSEN2), and 22q (NF2). 
Th e presence of loss of heterozygosity (LOH) and new alleles 
consistent with microsatellite instability (MSI) was investigated 
using PCR and quantitative capillary electrophoresis of DNA 
extracted from each microdissected target ( 26,28,29,32 ). PCR-
amplifi able DNA was used to identify targets of adequate quality 
for use in assessing ML. If the extracted DNA was of low quality, 
then the DNA specimen was considered as nonassessable for that 
target and was not included in the ML calculation. Laboratory 
personnel and pathologists performing the microdissection and 
scoring the genetic loci were blinded to the progressor status of 
the tissue.
 ML analysis
 Th e ML is a summary construct to quantify the degree of cumula-
tive genetic derangement present at all 10 genomic loci assessed. 
ML was determined for each tissue target by considering the 
presence and clonality of LOH mutations and the presence of 
MSI at each genomic locus. Development of the ML algorithm 
has been previously described ( 26,32 ). In brief, all LOH muta-
tions at a genomic locus were assigned a numerical value based 
on the extent (clonality) of LOH. Clonality was determined using 
the ratio of allele peak heights in DNA from microdissected tar-
gets. LOH mutations were high clonality when greater than 75% 
of the DNA had LOH mutation, and low clonality when 50–75% 
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of the DNA had LOH mutation. A value of 0.5 was assigned 
for low-clonality mutations and 1 for high-clonality mutations. 
Th e value of the fi rst MSI at a genomic locus was 0.75, and for 
each additional MSI thereaft er was 0.5. Th e values for low- and 
high-clonality LOH mutations and MSI were used to calculate 
the highest weighted value at each locus, which were summed 
together for all loci in a tissue target. Th e resulting cumula-
tive value was defi ned as the overall ML for that tissue target, 
ranging from 0 to 10 in value (a high-clonality LOH mutation, 
weighted 1, was the highest possible weighted value at each of the 
10 genomic loci). Th e maximum ML present in all tissue targets 
for a patient’s baseline index biopsy was defi ned as the ML for the 
pre-progression tissue.
 Statistical analysis
 ML in pre-progression tissues of cases and controls was com-
pared to assess its ability to predict progression to HGD or EAC. 
Chi-square and Fisher’s exact tests were used to compare categori-
cal variables, and Wilcoxon rank-sum test was used for continuous 
variables. A box-and-whisker plot of ML in cases and controls was 
constructed. Receiver operator characteristic (ROC) curves were 
created to assess the diagnostic utility of various cutoff s of ML for 
progression, and the utility of subgroups of loci was assessed for pre-
dicting progression. Th e diff erence between ROC curves using dif-
ferent loci was tested using the nonparametric method established 
by Venkatraman and Begg ( 33 ). Logistic regression was performed 
including age, gender, and baseline index histology (i.e., NDBE and 
LGD) as covariates. Eff ects of these covariates were tested using 
the likelihood ratio test. Confi dence intervals for AUROC were 
calculated using the DeLong method ( 34 ). Linear discriminant 
analysis was performed to assess the eff ect of diff erential weighting 
of results from individual loci on assay accuracy. Given the vari-
ability of assessable targets, Monte Carlo simulations were used to 
determine the optimal number of microdissected histological tar-
gets needed to achieve maximum accuracy. Simulations were per-
formed by randomly selecting one, two, three, or more than three 
targets. Th e average performance of more than 100 simulations for 
each target number, per patient, at index time points was calculated. 
Two-tailed tests with the signifi cance level of  P <0.05 were used. All 
analyses were performed with the R statistical programming lan-
guage (r-project.org).
 RESULTS
 A total of 69 patients were included in the analysis, includ-
ing 46 nonprogressors (controls) and 23 progressors (cases). 
Th ere was no diff erence in average age between the two groups 
( Table 1 ). Typical of Barrett’s patients, the majority was male. 
Both groups had on average two assessable microdissected 
histological targets (range 1–8) per patient from the baseline 
(pre-progression) exam. Th ere was no signifi cant diff erence 
between the proportion of cases and controls harboring LGD 
at index biopsy (30.4 vs. 17.4%,  P =0.23). Th e mean follow-up 
time between index and outcome biopsies was 4 years for both 
cases and controls.
 Th e mean per-patient ML at index biopsy was signifi cantly 
higher in cases (mean ML=2.21) compared with controls (mean 
ML=0.42,  P <0.0001) ( Figure 1 ). Th e ML of progressors ranged 
from 0.5 to 6.75 and the ML of nonprogressors ranged from 0.00 
to 2.75. No case had an ML of 0 in their pre-progression tissue, 
compared with 25/46 (54%) of controls.
 To understand the operating characteristics, the test was evalu-
ated with diff erent per-patient ML cutoff s ranging from 0.5 to 
1.5 ( Table 2 ). As expected, sensitivity decreased and specifi city 
increased with increasing cutoff s for ML. Th ere was 100% sensi-
tivity for ML cutoff  ≥0.5 and 96% specifi city for ML cutoff  ≥1.5. 
Aft er adjusting for covariates, including age, gender, and histology 
of patient at index time point (NDBE or LGD), the adjusted odds 
 Table 1 .  Description of Barrett’s esophagus nonprogressor and 
progressor patients included in the study 
  Nonprogressors 
( n =46) 
 Progressors 
( n =23) 
 Mean age (years)  62.5  63.9 
 Male  35 (76%)  22 (96%) 
 Mean targets per patient  1.70  1.87 
 Range follow-up time (minimum–
maximum years) between baseline and 
outcome biopsies 
 1.1–9.0  1.2–11.5 
 Mean follow-up time (years) between 
baseline and outcome biopsies 
 4.3  3.9 
 Median follow-up time (years) between 
baseline and outcome biopsies 



















 Figure 1 .  Mutational load (ML) of each nonprogressor and progressor 
patient at baseline index time point. ML per patient was the maximum 
ML in all microdissected histological targets at baseline time point for 
the patient. The most severe histology found in each patient’s clinical 
pathology report at that same index time point is indicated as intestinal 
metaplasia (IM) or low-grade dysplasia (LGD) (IM=orange circle; 
LGD=green circle). 
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ratio (OR) for identifying cases at ML ≥1 was 165.8 ( P <0.0001), 
compared with an unadjusted odds ratio of 146.7 ( P <0.0001). All 
covariates were statistically insignifi cant in both univariate and 
multivariate odds ratio analysis. Accuracy of the test was highest 
at 89.9% (95% confi dence interval (CI) 80.2–95.8) at ML ≥1. ROC 
curves were constructed with varying ML thresholds ( Figure 2 ), 
and the corresponding area under the curve (AUC) at ML ≥1 was 
0.95 (95% CI 0.89–1.0).
 Given that some genomic loci may be more predictive of pro-
gression than others, we assessed the frequency of mutations 
across the panel. Th ere was a fairly equal distribution of muta-
tions across all genomic loci in both groups ( Supplementary 
Table 1 online). All 10 loci showed a markedly higher rate of 
mutation in cases compared with controls. Th e most frequent 
locus in the control group was 9p. In the cases, the most frequent 
loci were 9p, 17p, and 5q.
 We then assessed the utility of simplifi ed models by using only 
the most predictive loci. Th ree ROC curves were compared: the 
fi rst, using all loci; the second, using data only from the three 
most predictive loci (9p, 17p, or 5q); and the third, using 9p alone 
( Figure 3 ). Th e best ROC curve was achieved when all 10 loci were 
used with AUC 0.95 (95% CI 0.89–1.0). ROC curves for the subset 
of 9p, 17p, or 5q had an AUC of 0.87 (95% CI 0.78–0.96). Th e worst 
curve was with 9p only, with an AUC of 0.73 (95% CI 0.61–0.85). 
Comparing the three ROC curves statistically demonstrated a 
 P value of 0.002 when comparing the 10 loci with 9p alone, 
a  P value of 0.07 when comparing 9p with 9p/17p/5q, and a  P value 
of 0.17 when comparing 9p/17p/5q with all loci.
 Th e optimal number of microdissected histologic targets needed 
for assessing ML performance was investigated by Monte Carlo 
simulation. ROC curves showed that the AUC for one target was 
0.88 (95% CI 0.83–0.94), compared with 0.94 (95% CI 0.89–0.99) 
for two targets, and 0.95 (95% CI 0.90–1.0) for three or more tar-
gets. Th erefore, classifi cation performance markedly improved 
when two or more microdissected histological targets were used 
for ML calculation, but it only modestly changed with additional 
targets.
 Finally, when a modifi ed ML calculation was tested by using 
variable weightings for each genomic locus, there was improved 
performance of ML with an AUC of 0.97, compared with the 
current method of ML calculation that had an AUC of 0.95. 
However, the diff erence between the two AUCs was not statisti-
cally signifi cant ( P =0.42), suggesting that the simple predefi ned 
scoring algorithm for ML, as described above, was about as 
accurate as the modifi ed loci-level weighted approach.
 DISCUSSION
 We performed a case–control study comparing ML in pre-progres-
sion tissue of BE subjects destined to develop HGD or EAC with 
controls who did not progress, to assess the diagnostic value of the 
ML in predicting progression. Th e AUC of the ROC curve for the 
assay at a cutoff  of ≥1 was 0.95. Th e test had the highest sensitivity 
at a threshold of ML ≥0.5. All loci that were tested for LOH and 
MSI provided value to predict progression to HGD or EAC. Test 
performance was highest when two or more microdissected histo-
logical targets were used. All 10 loci appeared to contribute to the 
 Table 2 .  Mutational load (ML) performance characteristics based 
on various per-patient ML thresholds derived from ROC curve 
  Per-patient ML threshold 
 Performance characteristic  ≥0.5  ≥1  ≥1.5 
 Sensitivity (%)  100.0  95.7  69.6 
 Specifi city (%)  54.3  87.0  95.7 
 Accuracy (%)  69.6  89.9  87.0 
 LR+  2.2  7.3  16.0 
 LR−  0.0  0.1  0.3 
 LR+, positive likelihood ratio; LR−, negative likelihood ratio; ROC, receiver operator 
characteristic. 






























 Figure 2 .  Receiver operator characteristic (ROC) for the performance 
of mutational load (ML) in predicting progression at baseline index 
time points for each patient. Area under the curve (AUC)=0.95 































 Figure 3 .  Receiver operator characteristic (ROC) for performance of muta-
tional load (ML) in predicting progression at baseline time points for each 
patient based on subsets of genomic loci included in ML calculations. 
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 Our study provides strong preliminary evidence for a robust 
biomarker calculated from genetic aberrations at multiple loci 
that can stratify risk in pre-progression BE tissue, and shows 
that these aberrations occur well before the onset of advanced 
neoplasia. One of the limitations of this study is that ML was 
derived from microdissected histological targets from archived 
pathology specimens. Th ere are potential problems with inad-
equate biopsies or missing dysplastic lesions, as these areas can 
be endoscopically diffi  cult to detect, and therefore sampling 
error may occur. However, sampling error leading to misclassi-
fi cation of patients with dysplasia as nondysplastic BE presum-
ably would bias our results toward the null, making it less likely 
that we would observe the strongly positive results reported here. 
In addition, there is known variability between pathologists on 
histologic classifi cation, which defi ned case and control groups. 
Histologic misclassifi cation is an unavoidable problem when 
developing tissue-based biomarkers if histologic readings are 
to be the “gold standard” against which the biomarker is to be 
measured. In addition, the size of the data set limited the evalu-
ation of genomic loci-level-based weighting in the modifi ed ML 
score, and made it impossible to test for DNA marker-level-
based ML scores that could potentially outperform the current 
ML system. Finally, as the rate of progression in BE is low, fur-
ther examination of ML in larger cohorts will be necessary to 
more completely understand the clinical utility of the assay in 
low-risk populations.
 Dysplasia surveillance in BE is a challenging and costly prob-
lem. Current surveillance methods based on histological classi-
fi cation are inaccurate and inadequate in predicting progression 
to HGD or EAC in patients with low-risk BE. Biomarkers are 
desperately needed, which accurately stratify risk in BE patients. 
Better risk stratifi cation will have implications in the frequency 
of surveillance endoscopy, as well as treatment decisions for 
ablative therapy in high-risk individuals. Th e results of this study 
provide support for the potential use of ML as a predictive bio-
marker in low-risk BE patients to assess for the risk of progres-
sion to malignancy.
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assay’s accuracy and modifi ed calculations with optimized weight-
ings of genomic loci did not markedly improve accuracy, suggesting 
that the simple summative model is appropriate to carry forward 
for clinical work. Th erefore, our preliminary study demonstrates the 
potential utility of using ML as a biomarker that predicts progres-
sion to dysplasia in patients with BE.
 Th e genetic instability associated with the progression of BE to 
EAC provides the conceptual underpinnings for the use of ML 
as a biomarker ( 35–39 ). Previous studies showed that increas-
ing ML, as used in our study, correlated with worsening BE 
histological classifi cation ( 32 ). Th is work demonstrated that ML 
distinguished patients with EAC from those without EAC, but 
did not determine when the biomarker appeared before occur-
rence of HGD or EAC. Given these fi ndings, it was important 
to understand the temporal relationship between changes in ML 
and progression to advanced neoplasia. For a biomarker to have 
clinical utility in BE, it needs to distinguish between high-risk 
and low-risk patients well before progression to carcinoma, to 
allow for early intervention. As the mean time between the base-
line and follow-up biopsies showing progression was 4 years in 
our study, our data suggest that the changes in ML predate the 
development of histological progression by a suffi  cient period, to 
allow this assay to be a clinically useful biomarker for predicting 
risk of progression.
 Previous investigators have assessed genetic changes asso-
ciated with progression in BE. Multiple loci differentiating 
between benign and malignant BE tissue have been identi-
fied in cross-sectional studies ( 30,31,40 ). Longitudinal studies 
in BE have often focused on a single genomic locus such as 
17p ( 41,42 ), and as a result may have limited clinical utility. A 
prospective 10-year study ( 43 ) found that 9p LOH, 17p LOH, 
and DNA content abnormalities were best at predicting 
progression to EAC (RR 38.7; 95% CI 10.8–138.5;  P <0.001), 
but it was limited owing to the small number of cancers occur-
ring in the sample. Another biomarker panel using a com-
bination of LGD and abnormal DNA copy number was able 
to identify 24% of BE progressors before the development 
of EAC ( 21 ). DNA methylation-based assays have shown a 
sensitivity of up to 50% in predicting progression to EAC 
( 44–46 ). Other genetic studies have focused on microRNA 
expression ( 47,48 ), genetic instability, and clonal expansion 
( 39 ), and transcribed ultraconserved non-coding RNAs ( 49 ), 
among other techniques ( 50,51 ), to determine elements of 
genetic aberration that can be used as predictors of carcino-
genesis in BE.
 Th e assay in our study was 100% sensitive at a threshold of ML 
≥0.5 and 89.9% accurate at a ML of ≥1 in diff erentiating between 
cases and controls. High sensitivity is a key for a molecular 
marker to detect disease states such as EAC that can have dire 
clinical consequences if missed. Th erefore, this assay at a thresh-
old of ML ≥0.5 demonstrates adequate promise to proceed with 
the next phase of biomarker development ( 52 ), a larger prospec-
tive trial, to more completely determine the operating character-
istics of the test.
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 Study Highlights
 WHAT IS CURRENT KNOWLEDGE 
 ✓  Barrett’s esophagus is a precursor to esophageal adeno-
carcinoma (EAC). Early detection of high-grade dysplasia 
(HGD) and EAC allows endoscopic intervention. 
 ✓  Current surveillance techniques are based on random 
histologic samples and are imperfect predictors of disease 
progression. 
 ✓  There is a need for alternate methods of risk stratifi cation 
in Barrett’s esophagus. 
 WHAT IS NEW HERE 
 ✓  We performed a case–control study to assess a genetic 
panel to calculate mutational load (ML) that can be used 
to predict which patients will progress to dysplasia. 
 ✓  Mean ML was higher in the pre-progression tissue in low-
risk Barrett’s patients who progressed to HGD or EAC. 
 ✓  ML at a threshold of ≥0.5 was 100% sensitive at predict-
ing progression. 
 ✓  ML maybe a clinically useful biomarker for risk stratifi ca-
tion, and it needs to be further tested in a prospective trial 
to more completely characterize its utility as a predictive 
marker of neoplastic progression in Barrett’s esophagus. 
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